Apogee Therapeutics (APGE) Payables (2022 - 2026)

Apogee Therapeutics (APGE) has reported Payables for 5 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables fell 49.41% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (down 49.41% YoY), while the FY2025 annual figure was $1.2 million, up 14.01% from the prior year.
• Payables climbed to $1.2 million in Q1 2026 per APGE's latest filing, from $1.2 million in the prior quarter.
• Across five years, Payables topped out at $11.1 million in Q2 2023 and bottomed at $376000.0 in Q3 2025.
• Historically, Payables has averaged $3.0 million across 5 years, with a median of $2.1 million in 2023.
• Annual changes were most pronounced in 2023 — Payables soared 412.68% — and 2025, when it sank 83.03%.
• Apogee Therapeutics' Payables stood at $418000.0 in 2022, then jumped by 412.68% to $2.1 million in 2023, then sank by 50.02% to $1.1 million in 2024, then increased by 14.01% to $1.2 million in 2025, then grew by 1.31% to $1.2 million in 2026.
• Business Quant data shows APGE's Payables at $1.2 million in Q1 2026, $1.2 million in Q4 2025, and $376000.0 in Q3 2025.